A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer

NCT ID: NCT01829841

Last Updated: 2018-05-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-05-31
• Study Completion Date: 2016-05-31

Brief Summary

• Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable.
• The purpose of this study is to compare the efficacy and safety profile between Famitinib and Sunitinib in patients with metastatic renal cell carcinoma.

Conditions

Renal Cell Cancer; Metastatic Renal Cell Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Famitinib

Famitinib 25 mg qd p.o., 6 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.

Group Type: EXPERIMENTAL

Famitinib

Intervention Type: DRUG

Famitinib 25 mg p.o. qd

Sunitinib

Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.

Group Type: ACTIVE_COMPARATOR

Sunitinib

Intervention Type: DRUG

Sunitinib 50 mg p.o. qd

Interventions

Famitinib

Famitinib 25 mg p.o. qd

Intervention Type: DRUG

Sunitinib

Sunitinib 50 mg p.o. qd

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with histologically confirmed advanced renal cell carcinoma including clear cell component and not available for surgery
• First-line therapy or second-line treatment (second-line treatment e.g chemotherapy or cytokine therapy as first-line treatment failure or resistant patients)
• With measurable disease (using RECIST1.0 standard conventional CT scan ≥ 20 mm, spiral CT scan ≥ 10mm, target lesion did not receive radiation therapy, cryotherapy)
• Male or female, age ≥18 and ≤75
• ECOG 0-1
• Life expectancy ≥ 3 months
• Subjects received surgery, chemotherapy, radiation therapy, cytokines treatment caused the damage has been restored, the time interval ≥ 4 weeks, and the wound has completely healed
• Normal major organ function
• Signed and dated informed consent

Exclusion Criteria

• Previously received targeted therapy of the metastatic renal cell carcinoma (such as sunitinib, Sorafenib)
• Past or suffering from other cancer, but other than cure basal cell carcinoma and cervical carcinoma in situ
• Participated in other clinical trials within four weeks
• A variety of factors that affect the oral medication (such as inability to swallow, gastrointestinal resection, chronic diarrhea and intestinal obstruction)
• Known brain metastases, spinal cord compression, cancer, meningitis, or screening CT or MRI examination revealed brain or leptomeningeal disease
• Patients with hypertension (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg). Patients with more than Class I, myocardial ischemia or myocardial infarction, arrhythmia (including QT interval ≥ 440ms) and class I heart failure.
• Urine protein ≥ + + and confirmed the 24-hour urinary protein>1.0 g
• Coagulopathy with bleeding tendency (such as active peptic ulcer) or are receiving thrombolytic or anticoagulant therapy
• Previous hyperactivity / venous thromboembolic events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis and pulmonary embolism
• The preexisting abnormal thyroid function, even in the case of medication still can not be maintained within the normal range
• With a history of abuse of psychotropic drugs or mental disorders
• Patients with Hepatitis B or Hepatitis C
• History of immunodeficiency, including HIV testing positive or suffering from acquired, congenital immunodeficiency disease, or a history of organ transplantation

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

Sponsor Role: collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jinwan Wang, M.D

Role: STUDY_CHAIR

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Jianhui Ma, M.D

Role: STUDY_CHAIR

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Locations

Cancer Institute and Hospital Chinese Academy of Medical Sciences

Beijing, , China

Countries

China

Other Identifiers

FMTN-II-MRCC

Identifier Type: -

Identifier Source: org_study_id